Perilesional heberferon in the treatment of basal cell carcinoma of high risk
Keywords:
heberferón, basal carcinomaAbstract
The HeberFERON is a formulation that contains a synergetic combination of interferons alpha 2b and gamma, with anti-proliferative, immune modulating, anti-angiogenic and antitumoral properties. The basal carcinoma (CBC) is the most common type of skin cancer. It is considered like a locally invasive, aggressive and destructive malignant tumor, but rarely metastasize. We report the case of a patient with recurrent Basal Carcinoma located in nasal right wing, of 4 centimeters and loss of the cartilage, in which the conventional surgery had been practiced.
Objective: Reporting the case of a patient with high-risk CBC previously treated by surgical way 8 years ago, that shows tumoral recidive in similar place, nasal right wing.
Case presentation: Feminine patient, phototype III, of 69 years of age, operated on in the 2008 due to a tumoral lesion of 5 millimeters in nasal right wing, the histological study evidenced a nodular pigmented CBC that compromised its reticular dermis, with the tumor inside the borders of section surgical, they did not report if in the studied sample perineural invasion was found.
The lesion reappears in the term of a year and when we evaluate the patient in April of 2016 we found, to the physical examination, a 4-centimeter lesion frankly nodular, infiltrated and lobed, with loss of the nasal cartilage. A dermatoscopy study that showed an image in maple leaf, in wheel of carts, arboriform vessels, as well as points and globules that suggest nests of basaloid cells.
The patient refuses to a re-intervention and to be about a lesion in right nasal wing recurrent, we propose perilesional treatment with Heberferón 3,5 million three times per week, during three weeks with 9 administrations’ total if it was confirmed, with a histological reassessment, the presence of a CBC and if when carrying on studies of blood chemistry and in the case history, the patient fulfilled the criteria established according to protocol for the administration of the product.
Operated in the 2004 to present Duct Carcinoma of left breast, performing a cuandrantectomy and Radiation Therapy.
Downloads
Published
How to Cite
Issue
Section
License
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
